Schering: MS drug reduces onset by 50%
Schering has unveiled Phase III trial data that shows its multiple sclerosis drug Betaferon reduced the risk of developing the disease among early-stage patients by 50 percent. Schering said it will seek approval for a wider use of the drug by expanding its label. That would help enhance sales of the drug, which hit $939 million last year. The data was presented at the European Committee for Treatment and Research in Multiple Sclerosis conference in Greece.
- read this story from AFX for more
Paid Research Reports
- RNA therapy: the next big thing after monoclonal antibodies?
- Biotech M&A Strategies: Deal assessments, trends and future prospects
- The Dermatology Market Outlook to 2013: Competitive landscape, pipeline analysis and growth opportunities
- Pipeline Insight: Cancer Overview - Breast, Gynecological, Genitourinary - Diverse drugs approaching the market for many tumor t
- Sales Force Effectiveness
- Forecast Model: Antidyslipidemics - Genericization and negative trial data drive market shrinkage
